Eric Yarnell1. 1. Department of Botanical Medicine, Bastyr University, 14500 Juanita Dr NE, Kenmore, WA 98028, USA; Chief Medical Officer, Northwest Naturopathic Urology, 3670 Stone Wy N, Seattle, WA 98103, USA. Tel.: +1 206-834-4100;
Abstract
OBJECTIVE: To determine if oral artemisinin is safe and has a short-term effect on prostate specific antigen (PSA) kinetics in patients with prostate cancer (CaP). DESIGN: Retrospective case series. SETTING: A private naturopathic urology clinic in Seattle, WA. PATIENTS: All artemisinin-treated CaP patients were identified retrospectively between 2005 and 2008. A total of 15 patients were identified who had taken artemisinin and included in the study, comprising 5 patients who had previously undergone radical prostatectomy (RP) and were having biochemical recurrences as well as 10 patients with no prior conventional therapy for CaP. INTERVENTIONS: High-dose, pulsed oral artemisinin 300-400 mg three times a day every other week for 3-24 months (median 9.5 months, IQR 5-12 months). All patients were treated with an array of other naturopathic therapies. OUTCOME MEASURES: The primary outcomes were the PSA doubling time and velocity; secondary outcome measures were signs and symptoms of metastasis and survival. RESULTS: Of those patients who have previously undergone RP, 2/5 (40%) had improved PSA kinetics after artemisinin therapy. Of those with no prior RP, 5/10 (50%) had improved PSA kinetics. No patient developed signs of metastasis and no patients died. There were no reported adverse effects. CONCLUSIONS: This pilot study provides preliminary evidence to suggest that high-dose, pulsed oral artemisinin therapy may have activity in patients with CaP. A larger controlled trial is warranted to confirm these preliminary beneficial effects.
OBJECTIVE: To determine if oral artemisinin is safe and has a short-term effect on prostate specific antigen (PSA) kinetics in patients with prostate cancer (CaP). DESIGN: Retrospective case series. SETTING: A private naturopathic urology clinic in Seattle, WA. PATIENTS: All artemisinin-treated CaP patients were identified retrospectively between 2005 and 2008. A total of 15 patients were identified who had taken artemisinin and included in the study, comprising 5 patients who had previously undergone radical prostatectomy (RP) and were having biochemical recurrences as well as 10 patients with no prior conventional therapy for CaP. INTERVENTIONS: High-dose, pulsed oral artemisinin 300-400 mg three times a day every other week for 3-24 months (median 9.5 months, IQR 5-12 months). All patients were treated with an array of other naturopathic therapies. OUTCOME MEASURES: The primary outcomes were the PSA doubling time and velocity; secondary outcome measures were signs and symptoms of metastasis and survival. RESULTS: Of those patients who have previously undergone RP, 2/5 (40%) had improved PSA kinetics after artemisinin therapy. Of those with no prior RP, 5/10 (50%) had improved PSA kinetics. No patient developed signs of metastasis and no patients died. There were no reported adverse effects. CONCLUSIONS: This pilot study provides preliminary evidence to suggest that high-dose, pulsed oral artemisinin therapy may have activity in patients with CaP. A larger controlled trial is warranted to confirm these preliminary beneficial effects.
Authors: Gary J Kelloff; Donald S Coffey; Bruce A Chabner; Adam P Dicker; Kathryn Z Guyton; Perry D Nisen; Howard R Soule; Anthony V D'Amico Journal: Clin Cancer Res Date: 2004-06-01 Impact factor: 12.531
Authors: Digant Gupta; Christopher G Lis; Sadie L Dahlk; Pankaj G Vashi; James F Grutsch; Carolyn A Lammersfeld Journal: Br J Nutr Date: 2004-12 Impact factor: 3.718
Authors: Digant Gupta; Carolyn A Lammersfeld; Jessica L Burrows; Sadie L Dahlk; Pankaj G Vashi; James F Grutsch; Sara Hoffman; Christopher G Lis Journal: Am J Clin Nutr Date: 2004-12 Impact factor: 7.045
Authors: Thomas A Stamey; Mitchell Caldwell; John E McNeal; Rosalie Nolley; Marci Hemenez; Joshua Downs Journal: J Urol Date: 2004-10 Impact factor: 7.450
Authors: Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245